EPHA2 and neoplasm: GC with EphA2 overexpression may show a greater possibility of invisible metastasis (62), distant metastasis (63), tumor invasion, worse clinical staging (51, 56, 60, 64, 65), recurrence (62), tumor differentiation (60), and poor prognosis (64).